Juvenile Idiopathic Arthritis (JIA)NCT07709026
Short-Term Effects of Intra-Articular Corticosteroid Injection on Knee Function in Juvenile Idiopathic Arthritis
An observational study of Juvenile Idiopathic Arthritis (JIA), run by Necmettin Erbakan University at 1 site in Turkey (Türkiye).
Trial summary
The purpose of this study is to evaluate the short-term clinical effects of intra-articular corticosteroid injections on knee joint functions in children and adolescents diagnosed with Juvenile Idiopathic Arthritis (JIA). Read more about this study
- Who is it for?
- Ages 8 to 16 years
- Conditions the study is for
- Juvenile Idiopathic Arthritis (JIA)
- What is being tested?
- Intra-articular Corticosteroid Injection
- Type of treatment
- Injection or infusion
- How many people
- 17 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Nov 2022to 15 Aug 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 16 years
- All sexes
- No healthy volunteers
- Child
Study population: The study population consists of pediatric patients diagnosed with Juvenile Idiopathic Arthritis (JIA) who present with active unilateral or bilateral knee joint involvement. Participants include both newly diagnosed individuals and those under regular follow-up at a tertiary medical center's outpatient clinic, all of whom required clinical knee intra-articular corticosteroid injection (IACI) as part of their routine medical management.
Who may be able to join
- Patients diagnosed with juvenile idiopathic arthritis (JIA) according to standard criteria (arthritis with onset before the age of 16 years and duration longer than 6 weeks with no other identifiable cause).
- Having unilateral or bilateral active knee joint arthritis.
- Undergoing knee intra-articular corticosteroid injection (IACI) for the active knee joint involvement.
- Provision of written informed consent by both patients and their caregivers.
Who cannot join
- Presence of other chronic rheumatological diseases.
- Initiation or discontinuation of systemic steroids, conventional disease-modifying anti-rheumatic drugs (DMARDs) (e.g., methotrexate, sulfasalazine), or biologic DMARDs (e.g., inhibitors of TNF, IL-1, or IL-6) within the 3 months before knee IACI and during the follow-up period.
- History of severe adverse reactions to steroids.
- Presence of neurological diseases.
- History of lower extremity surgery.
- Missing data.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Necmettin Erbakan University, Faculty of Health Sciences
Konya
About this study
Official title: Short-Term Effects of Intra-Articular Corticosteroid Injection on Knee Function in Juvenile Idiopathic Arthritis: A Prospective Cohort Study
The purpose of this study is to evaluate the short-term clinical effects of intra-articular corticosteroid injections on knee joint functions in children and adolescents diagnosed with Juvenile Idiopathic Arthritis (JIA).
Patients who receive a corticosteroid injection into the knee joint as part of their routine medical treatment will be monitored prospectively. The study aims to assess changes in range of motion, functional status, and pain levels before the injection and during the early follow-up period after the procedure. This will help healthcare providers better understand the immediate benefits and functional outcomes of this treatment in youth sports and daily physical activities.
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Being tested
- Intra-articular Corticosteroid Injection
- Keywords
- Balance, gait, muscle strength, physical function
- Medical subject headings
- Arthritis, Juvenile
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intra-articular Corticosteroid InjectionDrug
Patients diagnosed with juvenile idiopathic arthritis (JIA) underwent a routine clinical knee intra-articular corticosteroid injection (IACI) due to active knee involvement. Clinical, functional, and physical strength assessments were performed prospectively at three specific time points: before the injection (baseline, T0), at 2 weeks post-treatment (T1), and at 2 months post-treatment (T2) to evaluate short-term outcomes.
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Pain Intensity
Pain intensity assessed at rest and during physical activity using a standard assessment scale.
Measured: Baseline (T0), 2 weeks (T1), and 2 months (T2) post-injection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start15 Nov 2022
- Primary completion15 Aug 2023
- Study completion15 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Juvenile Idiopathic Arthritis (JIA)Studies of the same condition, open and under way.
- More trials run by Necmettin Erbakan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- Necmettin Erbakan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Serdar Arslan, Necmettin Erbakan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07709026
- Sponsor's protocol ID
- 2022/311
- Status last verified
- Jul 2026
- First submitted
- 11 Jul 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Short-Term Effects of Intra-Articular Corticosteroid Injection on Knee Function in Juvenile Idiopathic Arthritis: A Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT07709026
- Acronym / sponsor ID
- 2022/311
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Keywords
- Balance, gait, muscle strength, physical function
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- Necmettin Erbakan UniversityUniversity, hospital or other
- Study start
- 15 Nov 2022 (actual)
- Primary completion
- 15 Aug 2023 (actual)
- Study completion
- 15 Aug 2023 (actual)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the short-term clinical effects of intra-articular corticosteroid injections on knee joint functions in children and adolescents diagnosed with Juvenile Idiopathic Arthritis (JIA).
Patients who receive a corticosteroid injection into the knee joint as part of their routine medical treatment will be monitored prospectively. The study aims to assess changes in range of motion, functional status, and pain levels before the injection and during the early follow-up period after the procedure. This will help healthcare providers better understand the immediate benefits and functional outcomes of this treatment in youth sports and daily physical activities.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 8 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- The study population consists of pediatric patients diagnosed with Juvenile Idiopathic Arthritis (JIA) who present with active unilateral or bilateral knee joint involvement. Participants include both newly diagnosed individuals and those under regular follow-up at a tertiary medical center's outpatient clinic, all of whom required clinical knee intra-articular corticosteroid injection (IACI) as part of their routine medical management.
Key inclusion criteria (4 listed)
- Patients diagnosed with juvenile idiopathic arthritis (JIA) according to standard criteria (arthritis with onset before the age of 16 years and duration longer than 6 weeks with no other identifiable cause).
- Having unilateral or bilateral active knee joint arthritis.
- Undergoing knee intra-articular corticosteroid injection (IACI) for the active knee joint involvement.
- Provision of written informed consent by both patients and their caregivers.
Key exclusion criteria (6 listed)
- Presence of other chronic rheumatological diseases.
- Initiation or discontinuation of systemic steroids, conventional disease-modifying anti-rheumatic drugs (DMARDs) (e.g., methotrexate, sulfasalazine), or biologic DMARDs (e.g., inhibitors of TNF, IL-1, or IL-6) within the 3 months before knee IACI and during the follow-up period.
- History of severe adverse reactions to steroids.
- Presence of neurological diseases.
- History of lower extremity surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intra-articular Corticosteroid InjectionPatients diagnosed with juvenile idiopathic arthritis (JIA) underwent a routine clinical knee intra-articular corticosteroid injection (IACI) due to active knee involvement. Clinical, functional, and physical strength assessments were performed prospectively at three specific time points: before the injection (baseline, T0), at 2 weeks post-treatment (T1), and at 2 months post-treatment (T2) to evaluate short-term outcomes. | Drug | – |
Primary outcome
Change from Baseline in Pain Intensity
Time frame: Baseline (T0), 2 weeks (T1), and 2 months (T2) post-injection
Pain intensity assessed at rest and during physical activity using a standard assessment scale.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
Related trials for Juvenile Idiopathic Arthritis (JIA)
RecruitingPhase 3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Recruiting
The Use of Infrared Cameras for Detecting Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis, Infrared Thermography
Not yet recruitingPhase 4
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA)
RecruitingObservational study
Tofacitinib in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA)
RecruitingPhase 3
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Juvenile Idiopathic Arthritis (JIA), run by Necmettin Erbakan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Pain Intensity (time frame: Baseline (T0), 2 weeks (T1), and 2 months (T2) post-injection). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026; AzTrials last refreshed its copy on 7 Nov 2026.